Coya Therapeutics Acquires Patent License to Advance Next Generation Immune Modulatory Biologics for Inflammatory Diseases, Boosting Regulatory T Cells
HOUSTON - Coya Therapeutics, a leading clinical-stage biotechnology company (NASDAQ: COYA), announced today a significant expansion of its patent portfolio to include the intellectual property rights for the incorporation of next generation immune modulatory biologics in combination with COYA 301 to enhance regulatory T cells (Tregs) in the treatment of inflammatory diseases. This latest license agreement, facilitated by UNeMed Corporation (UNeMed), the Technology Transfer Office of the University of Nebraska Medical Center, reinforces Coya’s commitment towards developing novel therapies that harness the power of Tregs in managing immune-mediated disorders.
As a company at the forefront of Treg-based therapy research, Coya has been focused on advancing its proprietary drug candidate, COYA 302, a combination therapy of COYA 301, a Treg expansion factor, with CTLA-4 Ig, a proven immunomodulatory molecule. However, in a strategic move aimed at bolstering its position in the realm of precision medicine, Coya Therapeutics has enhanced its patent estate by extending its intellectual property rights beyond COYA 302.
The newly acquired license encompasses the unique combination of COYA 301 with a select group of next generation immune modulatory biologics. This pioneering approach holds great promise in boosting the functional capabilities of regulatory T cells, which play a crucial role in maintaining immune homeostasis and preventing excessive inflammation. Through this novel combination, Coya Therapeutics aims to address the unmet medical needs of patients suffering from a wide range of inflammatory diseases, including autoimmune disorders and chronic inflammatory conditions.
Expanding our patent portfolio to encompass this groundbreaking combination therapy is a significant milestone for Coya Therapeutics, commented Dr. Rebecca McCoy, the Chief Scientific Officer at Coya Therapeutics. By incorporating these next generation immune modulatory biologics with COYA 301, our aim is to further enhance Treg function and overall immunomodulation, leading to improved patient outcomes and offering potential disease-modifying benefits.
Coya Therapeutics’ strategic alliance with UNeMed Corporation is a testament to the company’s commitment to collaborating with leading research institutions to accelerate scientific discoveries and translate them into effective therapies. By harnessing the expertise of the University of Nebraska Medical Center, renowned for its groundbreaking research in immunology, Coya Therapeutics is poised to revolutionize the treatment landscape for inflammatory diseases.
Comments